While the preferred embodiments of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming with the scope of the following claims is reserved.

What is claimed is:

1. A method of treating human prostatic adenocarcinoma which comprises administering to a subject in need thereof an oral dosage unit containing from about 1 mg. to about 500 mg. of a steroid 5-α-reductase inhibiting compound from 1-6 times during a twenty four hour period.

2. The method of claim 1 in which the steroid 5-a-5 reductase inhibiting compound is 17β-(N-tbutylcarboxamide)-androst-3.5-diene-3-carboxylic acid.

ţġ 4.14 cm may be dear at